Fully-Automated AMD Screening

Need for AMD Screening

Age-related macular degeneration (AMD) is the single largest cause for legal blindness among senior Americans. Non-neovascular or dry (atrophic) AMD is the primary form of AMD contributing to 85% of the AMD cases and may be asymptomatic or result in a gradual vision loss. The largest and most impactful dry AMD studies - Age-Related Eye Disease study (AREDS) and Age-Related Eye Disease study 2 (AREDS2) - have shown that vitamin supplements along with minerals and antioxidants slow progression of the disease in patients with intermediate AMD, and those with late AMD in one eye. But without a straightforward, reliable way to screen for these vulnerable patients, early detection and treatment will remain a problem.


What is EyeSeeAMD™?

EyeSeeAMD™ is designed to be a fully automated retinal imaging analysis technology to identify AMD, the number-one cause of legal blindness in seniors. EyeSeeAMD will fully automate the screening, grading and reporting process, without need for a human grader and with high sensitivity and specificity. This will enable a primary eye care provider or optometrist to screen for AMD, which is possible today only in a specialist’s office, offering the potential to identify and treat far more patients than is possible today.

The EyeSeeAMD technology is based on the novel identification and quantification of drusen – deposits under the retina that are indicators of AMD – viewable in color fundus images and analyzed by the proprietary imaging software.

icon Technology behind EyeSeeAMD™

Our image analysis algorithms represent cutting-edge of research in image processing, computer vision, and machine learning. Technological innovations like morphology-inspired filter bank descriptors can automatically analyze fundus images to detect and localize lesions resulting from AMD.

Signup to stay up-to-date on Eyenuk's products!



* This product was supported by Award numbers R44EB013585, R42TR000377, R43EY024848, and R43EY025984 from the National Institutes of Health (NIH). The content is solely the responsibility of Eyenuk, Inc. and does not necessariliy represent the official views of NIH.
** This device is covered by one or more of the following US patents and their foreign counterparts: 8879813, 8885901, 9002085, and 9008391. Additional patents are pending.

EyeSeeAMD™ has not yet been cleared for sales in the US or EU.